Emicizumab: A Review in Haemophilia A
Emicizumab (Hemlibra®), a recombinant, humanized, bispecific monoclonal antibody, restores the function of missing activated factor VIII (FVIII) by bridging FIXa and FX to facilitate effective haemostasis in patients with haemophilia A. Subcutaneous emicizumab is approved in several countries, including in the USA and Japan, for the routine prophylaxis of bleeding episodes in patients with haemophilia A with or without FVIII inhibitors. It is also approved in the EU for the routine prophylaxis of bleeding episodes in patients with haemophilia A with inhibitors or severe haemophilia A without inhibitors. In phase III clinical trials, emicizumab prophylaxis significantly reduced annualized bleeding rates compared with no prophylaxis in adolescents and adults with haemophilia A with or without inhibitors, and prevented or substantially reduced bleeding in children with haemophilia A with or without inhibitors. Emicizumab was also associated with beneficial effects on health-related quality of life and health status, and was generally well tolerated. In view of its convenient route of administration and versatile dosage regimens (maintenance dose of once every 1, 2 or 4 weeks), emicizumab provides an effective and generally well-tolerated alternative to conventional FVIII replacement products for the prophylaxis of bleeding episodes in patients with haemophilia A, regardless of the presence or absence of inhibitors.
During the review process, the manufacturer of emicizumab was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
Conflict of interest
Hannah Blair is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.
The preparation of this review was not supported by any external funding.
- 4.Genentech Inc. Hemlibra® (emicizumab-kxwh) injection, for subcutaneous use: US prescribing information. 2018. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2483adba-fab6-4d1b-96c5-c195577ed071. Accessed 9 Sept 2019.
- 5.Chugai Pharmaceutical Co Ltd. Chugai’s Hemlibra® subcutaneous injection receives approval for hemophilia A without inhibitors and extension of dosing interval [media release]. 21 Dec 2018. http://www.chugai-pharm.co.jp/english/news/detail/20181221153002_580.html.
- 6.Roche. Hemlibra solution for injection: summary of product characteristics. 2019. http://www.ema.europa.eu/en/documents/product-information/hemlibra-epar-product-information_en.pdf. Accessed 9 Sep 2019.
- 16.Adamkewicz J, Schmitt C, Calatzis A, et al. Pharmacodynamic data and coagulation biomarkers in persons with hemophilia A (PwHA) with inhibitors: results from the HAVEN 1 emicizumab (ACE910) phase 3 study [abstract no. OC 47.1]. Res Pract Thromb Haemost. 2017;1(Suppl 1):162.Google Scholar
- 17.Kiialainen A, Schmitt C, Oldenburg J, et al. Pharmacokinetics and biomarkers in persons with haemophilia a (PwHA) without FVIII inhibitors receiving emicizumab once weekly in the phase 3 HAVEN 3 study [abstract no. P022]. Haemophilia. 2019;25(Suppl 1):46–7.Google Scholar
- 18.Kiialainen A, Schmitt C, Adamkewicz JI, et al. Pharmacokinetics and biomarkers in persons with haemophilia a (PwHA) receiving emicizumab every 2 or 4 weeks [abstract no. P021]. Haemophilia. 2019;25(Suppl 1):45–6.Google Scholar
- 22.Jimenez-Yuste V, Klamroth R, Castaman G, et al. A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of prophylactic emicizumab in persons with haemophilia A (PwHA) with FVIII inhibitors (STASEY): interim analysis results [abstract no. OC 60.3]. Res Pract Thromb Haemost. 2019;3(Suppl 1):116–7.Google Scholar
- 25.Callaghan MU, Kuebler PJ, Gao L, et al. Characterization of the impact of prior ITI on patient outcomes in HAVEN1 [abstract]. Am J Hematol. 2018;93(9):e10–1.Google Scholar
- 26.Mancuso ME, Oldenburg J, Callaghan M, et al. Emicizumab prophylaxis in adolescent/adult patients with haemophilia A previously receiving episodic or prophylactic bypassing agent treatment: updated analyses from the HAVEN 1 study [abstract no. BSH18-PO-146]. Br J Haematol. 2018;181(Suppl 1):127.Google Scholar
- 28.Skinner M, Negrier C, Paz-Priel I, et al. Emicizumab prophylaxis improves long-term physical health scores in persons with haemophilia A (PwHA) with and without inhibitors: update from the HAVEN 3 and HAVEN 4 studies [abstract no. PB0698]. Res Pract Thromb Haemost. 2019;3(Suppl 3):328–9.Google Scholar
- 30.Mancuso ME, Mahlangu J, Sidonio RF, et al. Emicizumab prophylaxis in paediatric persons with haemophilia A (PWHA) with inhibitors: impact on health-related outcomes and caregiver burden in the HAVEN 2 study [abstract no. OR10]. Haemophilia. 2018;24(Suppl 1):28–9.Google Scholar
- 31.Santagostino E, Oldenburg J, Chang T, et al. Surgical experience from four phase III studies (HAVEN 1-4) of emicizumab in persons with haemophilia A (PwHA) with or without FVIII inhibitors [abstract no. OC 60.1]. Res Pract Thromb Haemost. 2019;3(Suppl 1):115.Google Scholar
- 32.Callaghan M, Negrier C, Paz-Priel I, et al. Emicizumab treatment is efficacious and well tolerated long term in persons with haemophilia A (PwHA) with or without FVIII inhibitors: pooled data from four HAVEN studies [abstract no. OC 60.2]. Res Pract Thromb Haemost. 2019;3(Suppl 1):116.Google Scholar
- 36.National Hemophilia Foundation. Recommendation on the use and management of emicizumab-kxwh (Hemlibra®) for hemophilia A with and without inhibitors. 2018. http://www.hemophilia.org. Accessed 9 Sept 2019.
- 43.Adamkewicz J, Kim B, Steinbuesch D, et al. Measurement of FVIII inhibitor titer using a chromogenic Bethesda assay (CBA) in the presence of emicizumab (ACE910), a humanized bispecific antibody mimicking FVIIIa cofactor function [abstract]. Haemophilia. 2017;23(Suppl 3):3–4.Google Scholar
- 45.US National Institutes of Health (2019) http://www.clinicaltrials.gov. Accessed 9 Sept 2019
- 47.Escuriola-Ettingshausen C, Sidonio RF Jr, Oldenburg J, et al. Modern treatment of inhibitor-positive patients with haemophilia A (MOTIVATE)—an international observational study [abstract no. PB1406]. Res Pract Thromb Haemost. 2019;3(Suppl 1):423.Google Scholar
- 49.Institute for Clinical and Economic Review. Emicizumab for hemophilia A with inhibitors: effectiveness and value. 2018. http://icer-review.org/wp-content/uploads/2017/08/ICER_Hemophilia_Final_Evidence_Report_041618.pdf. Accessed 9 Sept 2019.